This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flack, J. M. Articles by Saunders, E. Search for Related Content PubMed PubMed Citation Articles by Flack, J. M. Articles by Saunders, E.

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

John M. Flack, MD, MPH^*,*, Suzanne Oparil, MD, J. Howard Pratt, MD, Barbara Roniker, MD, Susan Garthwaite, PhD, Jay H. Kleiman, MD, MPA, Yonghong Yang, PhD, Scott L. Krause, BSN, Diane Workman, PhD and Elijah Saunders, MD^||

^* Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA
Department of Medicine, University of Alabama, Birmingham, Alabama, USA
Department of Medicine, Indiana University School of Medicine and The Veterans Administration Medical Center, Indianapolis, Indiana, USA
Cardiovascular/Metabolic Diseases, Pharmacia Corporation, Skokie, Illinois, USA
^|| Division of Hypertension, University of Maryland, Baltimore, Maryland, USA

View larger version (22K): [in a new window]   Figure 1 Mean change from baseline for diastolic blood pressure (DBP) in (A) black patients and (B) white patients. Diamonds = placebo; squares = eplerenone; triangles = losartan. *p 0.05, **p 0.01, ***p 0.001 for eplerenone versus placebo or losartan.

View larger version (27K): [in a new window]   Figure 2 Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) associated with treatment according to baseline level of active renin. *p < 0.001 versus placebo and losartan; p < 0.01 versus placebo and losartan; p = 0.03 versus placebo; p = 0.002 versus placebo. White bars = <8.2 mU/l; lined bars = 8.2 and <13.4 mU/l; black bars = 13.4 mU/l.

View larger version (27K): [in a new window]   Figure 3 Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) associated with treatment according to baseline aldosterone level. *p < 0.03 versus placebo and losartan; p < 0.001 versus placebo; p < 0.005 versus placebo and losartan; p < 0.001 versus placebo, p = 0.033 versus losartan. White bars = <5.6 ng/dl; lined bars = 5.6 and <9.6 ng/dl; black bars = 9.6 ng/dl.